Literature DB >> 26850793

Neurothrombectomy in acute ischaemic stroke: a prospective single-centre study and comparison with randomized controlled trials.

O Nikoubashman1, M Jungbluth2, K Schürmann2, M Müller1, B Falkenburger2, S C Tauber2, M Wiesmann1, J B Schulz2,3, A Reich2.   

Abstract

BACKGROUND AND
PURPOSE: In the last few months five multicentre, randomized controlled trials (RCTs) unequivocally showed the superiority of mechanical thrombectomy in large vessel occlusion acute ischaemic stroke compared to systemic thrombolysis. Despite varying inclusion criteria and time intervals from onset to revascularization overall increases of good functional outcome between 55% and 81% were reported. However, only a minority of screened patients (approximately 1%) were eligible for intra-arterial (IA) therapy.
METHODS: An investigator-initiated, single-centre, prospective and blinded end-point analysis was performed of 3123 consecutive patients with acute ischaemic stroke presenting between February 2010 and December 2014.
RESULTS: One hundred and fifty-four patients [4.9%, age (years) mean (SD), median (interquartile range) 71.2 (±14), 74.7 (65.9-81.4)] met the inclusion criteria of sparse early ischaemic signs on initial standard cranial computed tomography (CT) (ASPECT score ≥7), large vessel occlusion in the anterior circulation on CT angiography and start of treatment within 6 h of onset of symptoms. After consensual interdisciplinary treatment decisions 130 patients (4.2%) received IA treatment - in the majority stent-assisted thrombectomy in combination with intravenous (IV) recombinant tissue plasminogen activator - and 24 patients (0.7%) standard IV thrombolysis. On 3 months' follow-up an overall significant improvement of disability (P = 0.05) as measured by the modified Rankin Scale was shown in favour of the IA treatment group. Good functional outcome was achieved in about twice as many patients (IA vs. IV, 41.2% vs. 21.2%; P = 0.078).
CONCLUSION: By choosing pragmatic inclusion criteria state-of-the-art IA therapy of a specialized tertiary stroke centre can be safely applied under real-world conditions to a higher percentage of patients with similar success to the recently published RCTs.
© 2016 EAN.

Entities:  

Keywords:  acute ischaemic stroke (AIS); neurothrombectomy; randomized controlled trials (RCTs); single-centre and real-world study

Mesh:

Substances:

Year:  2016        PMID: 26850793     DOI: 10.1111/ene.12944

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  6 in total

Review 1.  Endovascular Thrombectomy for Acute Ischemic Stroke.

Authors:  Tasneem F Hasan; Nathaniel Todnem; Neethu Gopal; David A Miller; Sukhwinder S Sandhu; Josephine F Huang; Rabih G Tawk
Journal:  Curr Cardiol Rep       Date:  2019-08-30       Impact factor: 2.931

2.  Influence of carotid tortuosity on internal carotid artery access time in the treatment of acute ischemic stroke.

Authors:  Z O Kaymaz; O Nikoubashman; M A Brockmann; M Wiesmann; C Brockmann
Journal:  Interv Neuroradiol       Date:  2017-09-24       Impact factor: 1.610

Review 3.  Endovascular Stroke Interventions: Procedural Complications and Management.

Authors:  Ahmed Elakkad; Gerald Drocton; Ferdinand Hui
Journal:  Semin Intervent Radiol       Date:  2020-05-14       Impact factor: 1.513

4.  Inducible Prostaglandin E Synthase as a Pharmacological Target for Ischemic Stroke.

Authors:  Lexiao Li; Nelufar Yasmen; Ruida Hou; Seyoung Yang; Jae Yeol Lee; Jiukuan Hao; Ying Yu; Jianxiong Jiang
Journal:  Neurotherapeutics       Date:  2022-01-31       Impact factor: 6.088

5.  Seeing the good in the bad: actual clinical outcome of thrombectomy stroke patients with formally unfavorable outcome.

Authors:  Friederike Blum; Charlotte Hager; Homan Taufik; Martin Wiesmann; Dimah Hasan; Arno Reich; João Pinho; Omid Nikoubashman
Journal:  Neuroradiology       Date:  2022-03-08       Impact factor: 2.995

6.  Improvement of Endovascular Stroke Treatment: A 24-Hour Neuroradiological On-Site Service Is Not Enough.

Authors:  Omid Nikoubashman; Kolja Schürmann; Ahmed E Othman; Jan-Philipp Bach; Martin Wiesmann; Arno Reich
Journal:  Biomed Res Int       Date:  2018-01-04       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.